Introduction {#S1}
============

GPCRs regulate diverse aspects of cellular and physiological responses and are considered therapeutic targets for intervening in numerous pathophysiological processes. A long-standing goal has been to understand how signalling specificity is achieved by a given GPCR. One way to achieve signalling specificity is through differential ligand affinity for different GPCRs, the long-recognized principle of *receptor selectivity.* Alternatively, ligands that bind the same GPCR can produce different effects by preferentially driving some downstream transduction pathways more strongly than others, the more recently recognized principle of *functional selectivity*. The present understanding of how functional selectivity occurs mechanistically is through differential stabilization of different GPCR conformational state(s) that shift receptor coupling from one G protein or arrestin mediator to another, the mechanism of *agonist bias*^[@R1],[@R2]^.

A new cellular principle for generating functional selectivity has emerged from the discovery that various GPCRs initiate signalling from more than one subcellular location. For example, β~2~-adrenoceptors (β~2~ARs) stimulate a Gs-mediated cAMP response both from the plasma membrane and from endosomes after ligand-induced internalization^[@R3]^, with the endosome-initiated cAMP signal preferentially coupling to downstream transcriptional control^[@R4]^. A number of other GPCRs also signal after endocytosis, and there is now considerable evidence supporting the hypothesis that the location of signal initiation can affect both the specificity and timing of downstream events^[@R5]-[@R7]^. All presently known examples of such *location bias* are based on signalling after ligand-induced endocytosis of receptors from the plasma membrane. We wondered if this principle might extend further, beyond the realm of receptors that require physical transfer from the cell surface to endomembranes and, if so, whether this might reveal additional potential for generating functional selectivity in GPCR-directed drug action according to location.

Here we identify such an additional mechanism through study of the β~1~-adrenoceptor (β~1~AR), a close relative of the β~2~AR that, unlike the β~2~AR, internalizes poorly via clathrin-coated pits after ligand-induced activation ^[@R8]^. We initially assumed that the β~1~AR would provide a counterexample to β~2~AR, with β~1~AR initiating signalling only from the plasma membrane. We show here that β~1~ARs not only initiate signaling from the plasma membrane, but also from the Golgi apparatus. We directly demonstrate Golgi-localized β~1~AR and Gs activation using conformational biosensor technology and develop a novel strategy to acutely and specifically inactivate the Golgi signal, demonstrating that this internal membrane pool can contribute significantly to the overall cellular cAMP response elicited by β~1~AR agonists. A remarkable and distinguishing feature of Golgi-localized β~1~AR activation is that it is mediated by a pre-existing Golgi-localized receptor pool, further differentiating it from endosome signalling and requiring ligands to access separately. We describe two modes of alternate ligand access to the Golgi-localized membrane pool and find, through direct monitoring of β~1~AR activity, marked differences among drugs presently used in the clinic as β-blockers. Our findings reveal a discrete cellular basis for achieving functional selectivity in GPCR-directed drug action through location bias and differential ligand access.

Results {#S2}
=======

Golgi-localized β~1~AR activation by catecholamines {#S3}
---------------------------------------------------

In adult cardiac myocytes endogenous β~1~AR but not β~2~AR has been shown to localize in a peri-nuclear distribution thought to represent nuclear membrane^[@R9]^. In these cells Golgi membranes are closely adjacent to the nuclear membrane, making them difficult to definitively resolve by light microscopy^[@R10],[@R11]^, and a fraction of β~1~AR clearly localize to the Golgi in various cell types^[@R12]^. It is not known if the Golgi localized fraction of β~1~AR represents simply a reserve pool or if it also plays a role in catecholamine signalling. To address this question, we utilized a biosensor of activated β~2~AR derived from a conformation-specific single-domain camelid antibody (Nb80) ^[@R3],[@R13],[@R14]^. We reasoned that this nanobody, which selectively binds the agonist-occupied β~2~AR, might also recognize activated β~1~AR based on extensive sequence homology in the region recognized by Nb80 ([Supplementary Results, Supplementary Fig 1a](#SD2){ref-type="supplementary-material"}). This proved to be the case; in β~1~AR expressing cells maintained in the absence of agonist, Nb80 fused to GFP (Nb80--GFP) localized diffusely through out the cytoplasm ([Fig. 1a](#F1){ref-type="fig"}, 0 min, top row). After application of the adrenergic endogenous ligand, epinephrine (10 μM) at 37°C, Nb80--GFP was rapidly recruited to the plasma membrane ([Fig. 1a](#F1){ref-type="fig"}, 2.5 min, middle row). Nb80--GFP was recruited to internal membranes two to three minutes later. Co-localization analysis defined Golgi membranes as a major site of epinephrine-induced Nb80-GFP recruitment ([Fig. 1a](#F1){ref-type="fig"}, 20min, bottom row, Pearson's coefficient= 0.67, see also [Supplementary Video 1](#SD2){ref-type="supplementary-material"}), overlapping the pool of Golgi-localized β~1~AR ([Fig 1c](#F1){ref-type="fig"}). These results suggest that the extracellular ligand promotes conformational activation of β~1~ARs not only the plasma membrane, but also in the Golgi apparatus.

To exclude a potential contribution of endogenous β~2~ARs we used the β~1~AR selective agonist, dobutamine, and pre-treated cells with a β~2~AR selective antagonist (ICI118551, 10μM). Robust Nb80-GFP recruitment to Golgi membranes was still observed, verifying that Golgi activation is mediated specifically by β~1~ARs ([Fig. 1b](#F1){ref-type="fig"}, Pearson's coefficient= 0.71, see also [Supplementary Video 2](#SD2){ref-type="supplementary-material"}).

The data so far suggest that Golgi localized β~1~AR achieve an activated conformation upon extracellular ligand application and shortly after receptor activation on the plasma membrane. We next investigated if activation of β~1~AR at the Golgi requires receptor activation on the plasma membrane and whether agonist is delivered to the internal membrane via receptor endocytosis. A number of agonists have been demonstrated to co-internalize with their cognate receptors into the same internal membrane compartment^[@R15]-[@R17]^. β~1~ARs, in contrast to β~2~ARs, display minimal internalization upon activation on the plasma membrane ([Fig. 1d](#F1){ref-type="fig"}) ^[@R8],[@R18]^ and this process has recently been proposed to require endophilin and dynamin but not clathrin^[@R19]^. To test whether activated β~1~AR on the Golgi is dependent on β~1~AR endocytosis from the plasma membrane, we used a dynamin inhibitor, Dyngo-4a, to acutely block all dynamin-dependent endocytosis mechanisms. Ligand-induced endocytosis of β~1~AR was undetectable in the presence of Dyngo-4a ([Fig. 1d](#F1){ref-type="fig"}) but ligand-induced recruitment of Nb80-mApple to Golgi membranes was still observed ([Fig. 1e](#F1){ref-type="fig"}, Pearson's coefficient= 0.5). This suggests that β~1~AR activation at the Golgi is independent of its activation at the plasma membrane. Supporting this, we found that sotalol, amembrane-impermeant antagonist that blocks β~1~AR activation selectively at the plasma membrane, had no effect on receptor activation at the Golgi by the membrane-permeant agonist dobutamine ([Supplementary Fig. 1b](#SD2){ref-type="supplementary-material"}, Pearson's coefficient=0.46). All together, these data suggest that β~1~AR resides on the Golgi at steady state and its activation by the extracellular ligand does not require receptor activation or internalization from the plasma membrane.

Golgi-localized β~1~ARs activate Gs {#S4}
-----------------------------------

Because the Golgi-localized β~1~AR pool can clearly undergo conformational activation, we next asked if receptors can activate their cognate G protein, Gs, at the Golgi. Heterotrimeric G proteins and adenylyl cyclase can be observed at the Golgi as well as the plasma membrane, supporting the concept of Golgi-based G protein signalling^[@R20]-[@R24]^. More recently, it has been demonstrated that activation of KDEL receptor by cargo transport from the endoplasmic reticulum to the Golgi triggers a cascade that involves Gs and adenylyl cyclase activation at Golgi membranes^[@R25]^. We observed detectable localization of both over-expressed and endogenous Gs on the Golgi at steady state ([Fig. 2a](#F2){ref-type="fig"}, Pearson's coefficient=0.62 and 0.48 for overexpressed and endogenous Gs, respectively). To directly investigate β~1~AR-mediated Gs activation at the Golgi, we utilized Nb37-GFP, which specifically recognizes a transient intermediate in the process of Gs activation and thus serves as a local Gs activation biosensor^[@R3],[@R26]^. Nb37--GFP localized in the cytoplasm of untreated cells and was rapidly recruited to the plasma membrane in response to agonist application and co-localized there with β~1~ARs ([Fig. 2b](#F2){ref-type="fig"}, white inset shows higher magnification on the right). Nb37--GFP was then recruited to Golgi membranes, with a strong signal observed within 20 minutes after agonist application ([Fig. 2b](#F2){ref-type="fig"}, yellow inset shows higher magnification on the right; Pearson's coefficient= 0.33), see also [Supplementary Video 3 and 4](#SD2){ref-type="supplementary-material"}).Golgi-localized Gs activation was indeed mediated by β~1~ARs because it was elicited also by the β~1~AR-selective agonist dobutamine ([Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}, Pearson's coefficient=0.6). All together, these data suggest that Gs associates with Golgi membranes at steady state and can be activated locally byβ~1~ARs in response to dobutamine.

Endogenous β~1~AR localizes at the Golgi and activates Gs {#S5}
---------------------------------------------------------

Endogenous β~1~AR has been shown to localize at the peri-nuclear regions in cardiac myocytes^[@R9]^. Additionally, previous studies using both biochemical fractionation and immunofluorescence microscopy, have provided evidence for Gs localization at Golgi membranes^[@R20],[@R24]^. To ask if activation of endogenous β~1~AR and Gs can occur at the Golgi, we examined H9C2 cells, a rat myoblast cell line that expresses endogenous β~1~ARs ^[@R27]^. Using an antibody recognizing native β~1~AR, we detected localization both to the plasma membrane and to Golgi membranes in H9C2 cells ([Fig. 2c](#F2){ref-type="fig"} top, Pearson's coefficient=0.55). We verified specificity of endogenous receptor detection by knocking down β~1~AR using two different siRNAs ([Fig 2c](#F2){ref-type="fig"} bottom, Pearson coefficient for β~1~AR si-2 and 3 = 0.26 and 0.29 respectively, full images of blots are shown in [supplementary Fig 3a](#SD2){ref-type="supplementary-material"}). Importantly, both Nb80-GFP and Nb37-GFP were recruited to Golgi upon addition of the β~1~AR-selective agonist dobutamine ([Fig. 2d](#F2){ref-type="fig"} top and bottom panels, respectively; also see [Supplementary Fig 2b](#SD2){ref-type="supplementary-material"}), as verified quantitatively by Pearson's correlation analysis of Nb80-GFP or Nb37-GFP localization relative to Golgi marker calculated before and after addition of dobutamine ([Supplementary Fig 3 b and c](#SD2){ref-type="supplementary-material"}). All together, these results indicate that endogenous β~1~ARs reside in the Golgi apparatus and can activate Gs from this location.

Golgi-localized β~1~ARs contribute tothe cAMP response {#S6}
------------------------------------------------------

Nb80 can be used to block β~2~AR-mediated signalling when expressed in the cytoplasm at high levels, presumably through steric occlusion of the β~2~AR--Gs binding interface, although this requires Nb80 to be present at much higher concentration than when used as an activation biosensor^[@R28]^. Because Nb80 also recognizes activated β~1~AR, and β~1~AR engages Gs in a similar manner as β~2~AR, we reasoned that Nb80 might be useful for blocking β~1~AR--Gs coupling as well. We further reasoned that, because signal inhibition requires Nb80 to be present at high concentration, that it might be possible to use Nb80 as a location-specific quencher through enforced proximity mediated by rapamycin-induced heterodimerization of the FK506-binding protein (FKBP) with the FKBP-rapamycin binding domain of FRAP (FRB)^[@R29]^. We fused FRB to the N-terminus of Nb80 (FRB-Nb80) and FKBP to a plasma membrane localization sequence derived from Lyn^[@R30]^ (PM-FKBP) or to the Golgi resident protein GalT (Golgi-FKBP). We verified rapamycin-induced recruitment of FRB-Nb80 specifically to the plasma membrane in cells co-expressing PM-FKBP ([Fig. 3a](#F3){ref-type="fig"}, top) and to Golgi membranes in cells co-expressing Golgi-FKBP ([Fig. 3a](#F3){ref-type="fig"}, bottom). Recruiting FRB-Nb80 to the plasma membrane partially reduced the β~1~AR-Gs cellular cAMP response elicited by dobutamine ([Fig. 3b](#F3){ref-type="fig"}, see also the time course in [Supplementary Fig 4a](#SD2){ref-type="supplementary-material"}). Chemical recruitment of FRB-Nb80 to Golgi membranes also produced a partial (and somewhat more pronounced) response inhibition ([Fig. 3c](#F3){ref-type="fig"}, see also the time course in [Supplementary Fig 4c](#SD2){ref-type="supplementary-material"}). Verifying specificity, rapamycin produced no significant change in the cAMP response elicited by forskolin, a direct activator of adenylyl cyclase ([Fig. 3d](#F3){ref-type="fig"}). Verifying that plasma membrane recruitment and Golgi recruitment of FRB-Nb80 suppress the cAMP response by inhibiting different pools of β~1~AR-Gs coupling, sotalol, a membrane-impermeant antagonist, produced an additive inhibitory effect in cells with FRB-Nb80 targeted to Golgi membranes but did not produce a significant additive effect in cells with FRB-Nb80 targeted to the plasma membrane ([Fig. 3 b and c](#F3){ref-type="fig"}, see also [Supplementary Fig 4a-c](#SD2){ref-type="supplementary-material"}). All together, these data suggest that Golgi-localized β~1~ARs can contribute significantly to the overall cAMP response.

Two modes of ligand access to the Golgi-localized β~1~AR pool {#S7}
-------------------------------------------------------------

A key question raised by these observations is how ligands gain access to Golgi-localized β~1~ARs. Whereas dobutamine is a drug that is even more hydrophobic than alprenolol (logP 3.4 compared to 3.1; pubchem.ncbi.nlm.nih.gov), a membrane-permeant ligand^[@R31]^, epinephrine is a relatively hydrophilic ligand (log P -1.4) and is membrane-impermeant. Therefore, while it seems likely that dobutamine can access the Golgi-localized receptor pool by passive diffusion, this cannot explain the ability of epinephrine to activate the Golgi pool ([Fig. 4a](#F4){ref-type="fig"}, table). A clue to resolving this conundrum came from the observation that epinephrine-induced activation of the Golgi-localized β~1~AR pool, assessed by Nb80-GFP recruitment, is blocked at low temperature ([Supplementary Fig 5a](#SD2){ref-type="supplementary-material"}-top row, Pearson's coefficient=0.21) while dobutamine-induced recruitment still occurs ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"} -bottom row, Pearson's coefficient=0.51). Additionally, these ligands differ in the kinetics with which they activate the Golgi pool at 37˚C, with dobutamine driving Golgi-localized Nb80-GFP recruitment more rapidly ([Supplementary Fig 5b](#SD2){ref-type="supplementary-material"}). Together, these results support the hypothesis that epinephrine accesses the Golgi-localized β~1~AR pool in a different manner than dobutamine, requiring a time- and temperature-dependent process distinct from passive diffusion.

We first considered the possibility that epinephrine accesses the Golgi β~1~AR pool by fluid phase uptake and vesicular transport. This appeared unlikely because fluorescent Dextran-647, a fluid phase uptake marker, was not detected in Golgi membranes and instead accumulated in distinct endosomal membranes ([Fig. 4b](#F4){ref-type="fig"}, Pearson's coefficient=0.18). We next considered the possibility that epinephrine accesses the Golgi pool through a membrane transporter. An extraneuronal monoamine transporter (EMT), also known as an organic cation transporter-3 (OCT3), has been shown to facilitate intracellular uptake of epinephrine and other catecholamines in cardiac cells^[@R32],[@R33]^. EMT/OCT3 expression was clearly detected in HeLa cells, whereas it was undetectable in HEK293 cells when assessed at either the mRNA or protein level ([Supplementary Fig 5c](#SD2){ref-type="supplementary-material"} and [Fig. 4c](#F4){ref-type="fig"}, full images of blots are shown in [supplementary Fig 6](#SD2){ref-type="supplementary-material"}). EMT/OCT3 is a bidirectional transporter protein that localizes to both the plasma membrane and intracellular membranes in cardiac cells ^[@R33]^, and we observed a similar localization in HeLa cells ([Fig. 4d](#F4){ref-type="fig"} and [Supplementary Fig. 5d](#SD2){ref-type="supplementary-material"}). Interestingly, the strong Golgi recruitment signal elicited bye pinephrinein HeLa cells ([Fig. 1a](#F1){ref-type="fig"}) was not observed in HEK293 cells ([Fig. 4e](#F4){ref-type="fig"}, middle row, Pearson's coefficient=0.26). Nevertheless, dobutamine remained able to stimulate Nb80-GFP recruitment to Golgi membranes in both cell types ([Fig. 4e](#F4){ref-type="fig"}, bottom row, Pearson's coefficient=0.63). A characteristic feature of EMT/OCT3 is that its transport activity is blocked by corticosterone ^[@R34]^ and, remarkably, pre-incubation of HeLa cells with corticosterone prevented epinephrine from driving visible Nb80-GFP recruitment to Golgi membranes while Nb80-GFP recruitment to the plasma membrane was unaffected ([Fig. 4f](#F4){ref-type="fig"}, middle row, Pearson's coefficient=0.15). By contrast, dobutamine-induced recruitment of Nb80-GFP to Golgi was not blocked in the same cells ([Fig. 4f](#F4){ref-type="fig"}, bottom row, Pearson's coefficient=0.68). All together, these data indicate that chemically distinct ligands can reach the Golgi membranes and activate Golgi-localized β~1~ARs using different mechanisms, diffusion in case of a hydrophobic agonist such as dobutamine and via extraneuronal monoamine transporters for the hydrophilic agonist epinephrine.

Epinephrine access to the Golgi-localized β~1~AR pool through a transporter-mediated process implies that this catecholamine is exposed to the cytoplasm for at least some time during transit. Cardiac cells express monoamine oxidase type A (MAO-A) on the mitochondrial outer membrane, and oxidative deamination catalysed by MAO-A is a major pathway of cytoplasmic epinephrine degradation^[@R35]^. HeLa cells are not known to express MAO-A, raising the question of whether the proposed route of epinephrine access to the Golgi-localized β~1~AR pool is plausible in cells that express this enzyme. To begin to investigate this, we overexpressed in HeLa cells a GFP-tagged MAO-A construct and then used Nb80-mApple as a biosensor to assess activation of the Golgi pool. Epinephrine was still able to produce clearly detectable activation of the Golgi-localized β~1~AR pool in cells that were verified (by GFP fluorescence) to express recombinant MAO-A ([Supplementary Fig. 5e](#SD2){ref-type="supplementary-material"}). This indicates that transporter-dependent activation of Golgi-localized β~1~ARs is plausible even in cells expressing MAO-A, but leaves unresolved if Golgi activation occurs in response to endogenous levels of catecholamine release.

Selective inhibition by β-blocker drugs {#S8}
---------------------------------------

We next considered the possibility that antagonists also differ in access to the Golgi-localized β~1~AR pool. Differences between antagonists in hydrophobicity are known to affect drug access to the central nervous system according to drug permeability across the blood-brain endothelial barrier^[@R36],[@R37]^. We hypothesized that a similar principle affects antagonist access to the Golgi-localized β~1~AR pool. If so, antagonist drugs could provide an independent means to investigate the contribution of Golgi-localized β~1~ARs to the overall cellular signalling response. To test this we compared the ability of metoprolol and sotalol, β~1~AR antagonists that differ \~50-fold in relative hydrophobicity and thus are anticipated to differ in membrane-permeance ([Fig. 5a](#F5){ref-type="fig"}, table). We tested relative access to each receptor pool by assessing effects on dobutamine-stimulated recruitment of Nb80-GFP.Metoprolol fully reversed Nb80-GFP recruitment to both the plasma membrane and Golgi membranes ([Fig. 5b](#F5){ref-type="fig"} top panel, also see [Supplementary Video 5](#SD2){ref-type="supplementary-material"}) whereas sotalol selectively blocked recruitment to the plasma membrane but not to Golgi membranes, even when applied at 10-fold higher concentration ([Fig. 5b](#F5){ref-type="fig"} middle and bottom panel, also see [Supplementary Video 6](#SD2){ref-type="supplementary-material"}). We then compared the ability of these antagonists to block the overall dobutamine-stimulated cellular cAMP response. Preincubation of cells with either metoprolol or sotalol significantly inhibited the cellular response([Fig. 5c and d](#F5){ref-type="fig"}, first two bars), consistent with the ability of both drugs to block plasma membrane activation. However, sotalol produced less inhibition even when applied at very high concentration ([Fig. 5c and d](#F5){ref-type="fig"}, light blue and grey bars 100μM and 5mM respectively). These findings further support the ability of Golgi-localized β~1~ARs to contribute to the overall cellular cAMP response and, as both metoprolol and sotalol are presently used as 'β--blockers', they suggest that differential access to the Golgi-localized pool may contribute to functional selectivity among clinically relevant antagonists.

The Golgi β~1~AR pool can locally activate PKA {#S9}
----------------------------------------------

Protein Kinase A (PKA) holoenzymes are localized to distinct subcellular locations through their association to A-kinase anchoring proteins (AKAPs). Major PKA holoenzymes, type I and type II, are distinguished by the identity of their regulatory subunits (RI or RII isoforms)^[@R38]^, with type II holoenzymes known to localize to the Golgi apparatus^[@R39]^.PKA activation by cAMP causes the Cα catalytic subunit to dissociate into the cytoplasm while RII regulatory subunits remain Golgi-associated^[@R40]-[@R42]^. To test whether activation of Golgi-localized β~1~AR can cause PKA activation on the Golgi membrane, we imaged both subunits of a type II holoenzyme (Cα-YFP and RIIβ-mCherry) in living cells. Dobutamine induced the rapid translocation of the Cα subunit from Golgi membranes to the cytoplasm in β~1~AR-expressing HeLa cells, whereas the RII subunit remained Golgi-localized ([Fig 6a and d](#F6){ref-type="fig"}, blue line; [Supplementary Video 7](#SD2){ref-type="supplementary-material"}). We then asked if this translocation can be elicited specifically by activation of the Golgi-localized β~1~AR pool. To test this we compared the effect of metoprolol and sotalol on dobutamine-induced PKA Cαtranslocation. The membrane-permeant antagonist metoprolol fully blocked PKA Cα Golgi translocation ([Fig 6c and d](#F6){ref-type="fig"}, red line; [supplementary Video 8](#SD2){ref-type="supplementary-material"}) whereas sotalol did not, even when applied at very high concentration (5mM) ([Fig 6b and d](#F6){ref-type="fig"}, grey line; [supplementary Video 9](#SD2){ref-type="supplementary-material"}). Further, dobutamine-induced dissociation of Cα from Golgi membranes was delayed in sotalol-treated cells, suggesting that plasma membrane and Golgi-localized β~1~AR pools promote activation of Golgi-localized PKA with distinct kinetics.

Discussion {#S10}
==========

The present findings provide direct evidence for adrenergic signalling from the Golgi apparatus and demonstrate that catecholamines can reach the internal pool to initiate canonical β~1~AR-Gs signalling from this location. Thus Golgi-localized β~1~ARs do not simply represent intermediates for later delivery to the plasma membrane, but they also comprise a functional signalling pool at this location. Selective inhibition of β-AR-Gs coupling by chemical recruitment of nanobody independently verifies the signalling potential of the Golgi-localized β~1~AR pool and introduces a new approach for functionally interrogating compartmentalized GPCR signalling more generally.

The present study provides evidence for two routes of ligand access to the Golgi localized β~1~AR pool. Drugs such as dobutamine access the Golgi pool by passive diffusion, determined largely by degree of lipophilicity^[@R43]^. The catecholamine agonist epinephrine is relatively hydrophilic and membrane-impermeantlig and whose access to the Golgi-localized β~1~AR pool requires OCT3, a member of the extraneuronal monoamine transporter (EMT) / organic cation transporter (OCT) family that is already known to function in cellular catecholamine uptake^[@R32]^. OCT3 exists both in the plasma membrane and internal membranes and can operate in a bidirectional manner^[@R43]^. Whether OCT3 is fully responsible for epinephrine uptake to the Golgi-localized β~1~AR pool, or if additional transporter(s) are also required or contribute, is an interesting question for future study. Another interesting question that remains to be answered is whether the transporter-dependent ligand access route is relevant to native β~1~AR signalling elicited by endogenously produced catecholamines or represents a drug-specific target.

The effect of different antagonists on the Golgi-localized signal has interesting implications for pharmacology.We speculate that differential drug access to the Golgi pool contributes to diversity in the clinical effects of existing β blocker drugs. Evidence suggests that metoprolol and propranolol, both hydrophobic antagonists, cause reduction of chronotropic (heart rate) and inotropic (force of contraction) responses, whereas sotalol can only cause a reduction in the heart rate^[@R44],[@R45]^. The present study has focused on cAMP signalling but we note that heterotrimeric G proteins are thought to also regulate membrane trafficking processes, both at the Golgi and in endosomes^[@R11],[@R25],[@R46],[@R47]^. Thus it is possible that differential drug effects on Golgi-localized β~1~AR activation may also have trafficking consequences.

The β~2~AR, a closely homologous adrenergic receptor, can mediate Gs signalling from endosomes as well as the plasma membrane ^[@R3]^, with the endosome-initiated signal preferentially promoting downstream cAMP-dependent transcription^[@R4]^. It remains unknown if Golgi-localized β~1~ARs also have distinct functions compared to plasma membrane localized β~1~ARs. Although both β~1~ARs and β~2~ARs couple to Gs and activate adenylyl cyclase, they have different effects on physiological responses such as regulating heart rate (chronotropic), contractility (inotropic) and the rate of relaxation (lusitropic) in cardiac myocytes^[@R8]^. β~1~AR plays a major role in regulating, inotropic and lusitropic effects, whereas β~2~AR mainly regulates chronotropic effects and have significantly smaller inotropic effect and no lusitropic effect^[@R48],[@R49]^. The underlying reasons for these distinctions remain unclear but there is already evidence that differences in downstream consequences of β~1~AR versus β~2~AR activation can result from differences in receptor localization between lateral microdomains of the plasma membrane^[@R50]^. The present results expand this concept by revealing that β~1~AR and β~2~AR initiate signalling from different internal membrane compartments and these are differentially accessible by ligands.

ONLINE METHODS {#S11}
==============

Cell Culture, cDNA constructs and transfection {#S12}
----------------------------------------------

HeLa, HEK293 and H9C2 cells (purchased from ATCC as authenticated lines CCL-2, CRL-1573 and CRL 1446 respectively) were grown in Dulbecco's minimal essential medium supplemented with 10% Fetal Bovine Serum (FBS)(UCSF Cell Culture Facility) without antibiotics. Cell cultures were free of mycoplasma contamination. pVenus-FRB-Nb80 was created by amplifying Nb80 and FRB from Nb80-GFP^[@R3]^, and pC~4~-R~H~E plasmid (ARIAD Pharmaceuticals), using 5'-CGAATCTCAAAGGATAGTGCTGGTAGTGCTGGTGGACAGGTGCA -3'; 5'- GGATCCTCATGAGGAGACGGTGACCTGGGT -3' and 5'- GAATTCAATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGA -3'; 5'- CGAATCTCAAAGGATAGTGCTGGTAGTGCTGGTGGACAGGTGCA -3 primers respectively, such that it contained the linker sequence GATAGTGCTGGTAGTGCTGGTGGAC, and inserted into the pVenus-C1 vector using EcoRI and BamH1. FKBP-GalT-mApple was created by amplifying FKBP and GalT from KDELr-FKBP^[@R47]^ and GalT-mCherry plasmids (a generous gift from Dr.Farese lab), using 5'- CATGCTAGCGCCGCCACCATGGGAGTGCAGGTGGAAACCAT-3', 5'-GAGCTCGAGACCAGCACTACCAGCACTATCCTCCAGCTTCAGCAGCTCCACG3' and 5'- GCTCAAAGCTTGCCGCCACCGGAAGGCTTCGGGAGCCG-3', 5'- ACCGGATCCTTAGGCCCCTCCGGTCCGGAGCTCCCCG-3' primers, respectively and inserted into the pmApple-N1 vector using NheI, XhoI for FKBP and HindIII and BamHI for GalT. Mouse PKA Cα-YFP and PKA RIIβ-mCherry constructs were generous gits from Dr. Xiang lab. Transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. ADRB1-2 (5'-CGUCCGUCGUCUCCUUCUATT-3') and 3 (5'GGGUGUUCCGCGAGGCCCATT-3') siRNAs (Qiagen) were used to knockdown β ARs. siRNA transfections were performed using RNAiMax (Invitrogen) according to the manufacturer's instructions. Flag tagged human βAR constructs were labelled with Alexa-647 or 555-conjugated M1 anti-FLAG monoclonal antibody (Sigma) as described previously ^[@R51]^. Anti-SLC22A3 antibody (abcam-ab124826) and anti-beta 1 adrenergic receptor antibody (abcam-ab3442) were used to detect endogenous levels of EMT/OCT3 and β1AR, respectively. Anti Gαs/olf antibody (SC-383) was used to detect endogenous Gαs in HeLa cells.

Live-cell confocal imaging {#S13}
--------------------------

Live cell imaging was carried out using Yokagawa CSU22 spinning disk confocal microscope with a 100 ×, 1.4 numerical aperture, oil objective and a CO~2~ and 37 °C temperature-controlled incubator. A 488, 568 nm and 640 Coherent OBIS laser were used as light sources for imaging GFP and Flag signals, respectively. Cells expressing both Flag-tagged receptor (2μg) and the indicated nanobody--GFP (100ng) were plated onto glass coverslips. Receptors were surface labelled by addition of M1 anti-Flag antibody (1:1000, Sigma) conjugated to Alexa 555 (A10470, Invitrogen) to the media for 10 min, as described previously. Indicated agonist (isoprenaline-Sigma, epinephrine-Sigma, dobutamine-Sigma), or antagonist (ICI 118551- TOCRIS, metoprolol-Sigma, sotalol-Sigma) were added and cells were imaged every 3 s for 20 min in DMEM without phenol red supplemented with 30 mM HEPES, pH 7.4 (UCSF cell culture facility). Time-lapse images were acquired with a Cascade II EM-charge-coupled device (CCD) camera (Photometrics) driven by Micro-Manager 1.4 (<http://www.micro-manager.org>).

Fixed-cell confocal imaging {#S14}
---------------------------

Cells were permeabilized with saponin to reduce the cytoplasmic background, as described previously^[@R52]^. Briefly, transfected cells with indicated constructs or non-transfected H9C2 cells were permeabilized with 0.05% saponin (Sigma) in PEM buffer (80mM K-Pipes, pH 6.8, 5 mM EGTA, 1mM MgCl2) for 5 min on ice. Cells were then fixed with 3% paraformaldehyde in PBS for 10 min and then quenched with 50mM Nh4Cl in PBS for 15 min. Primary antibodies (β1AR antibody (abcam-ab3442) 1:100, M1 anti-Flag mouse antibody (1:1000, Sigma) conjugated to Alexa 647, anti GFP mouse antibody (1:500, Sigma) and anti GFP Rabbit antibody (1:500, Life Technologies) were diluted in PBS supplemented with 0.05% saponin. Confocal images were taken using Yokagawa CSU22 spinning disk confocal microscope with a 100x or 60x 1.4 numerical aperture, oil objective.

Image analysis and statistical analysis {#S15}
---------------------------------------

Images were saved as 16 bit TIFF files. Quantitative image analysis was carried out on unprocessed images using ImageJ software (<http://rsb.info.nih.gov/ij>). Analysis of Nb80--GFP intensity profile along the segmented was carried out using the ImageJ plot profile function. For estimating kinetics of Nb80--GFP recruitment at the Golgi membrane over time in confocal images, individual cells were selected manually and average fluorescence intensity was measured at the Golgi area in each frame and normalized to the fluorescence intensity of the Golgi marker. A blank area of the image lacking cells was used to estimate background fluorescence. For estimating kinetics of PKACα YFP translocation from the Golgi membrane over time in confocal images, individual cells were selected manually and average fluorescence intensity was measured at the Golgi area in each frame and normalized to the fluorescence intensity of the PKA RIIβ-mCherry. A blank area of the image lacking cells was used to estimate background fluorescence. Co-localization analysis at the Golgi was estimated by calculating the Pearson's coefficient between the indicated image channels with the Golgi marker channel, using the co-localization plug-in for ImageJ (Coloc2).For visual presentation (but not quantitative analysis) image series were processed using Kalman stack filter in ImageJ.*P* values are from two-tailed unpaired Student's *t*-tests calculated using Prism 6.0 software (GraphPad Software).

Luminescence-based cAMP assay {#S16}
-----------------------------

HEK 293 cells stably expressing β~1~AR were transfected with a plasmid encoding a cyclic-permuted luciferase reporter construct, (pGloSensor-20F, Promega) and luminescence values were measured, as described previously^[@R3]^. Briefly, cells were plated in 24-well dishes (\~200,000 cells per well) in 500 μl DMEM without phenol red/no serum and equilibrated to 37 °C in a light-proof cabinet and images were collected every 10 s using a CCD camera (Hamamatsu C9100-13) and Micro-Manager (<http://www.micro-manager.org>).MATLAB (MathWorks)scripts were used to calculate integrated luminescence intensity and background subtraction.In rapamycin heterodimerization experiments, cells were pre-incubated with 1μM rapamycin (Sigma) for 15 min. 5μM forskolin was used as a reference value in each multi-well plate and for each experimental condition. The average luminescence value (measured across duplicate wells) was normalized to the maximum luminescence value measured in the presence of 5μM forskolin. For rapamycin treated cells, the average luminescence value was normalized to the maximum luminescence value measured in the presence of 5μM forskolin and 1μM Rapamycin.

Quantitative real-time PCR {#S17}
--------------------------

Total RNA was extracted from samples with RNeasy Mini Kit (Qiagen). Reverse transcription was carried out using SuperScript III RT (Invitrogen), mix of oligo (dT). The resulting cDNA was used for quantitative PCR with StepOnePlus (ABI). SYBER Select Mastermix (Invitrogen) was used for EMT/OCT3 expression measurements using 5'CCTTGTCTGTGTCAATGCGTGG3' and 5'CCAACACCAAGGCAGGATAGCA3' primers. All levels were normalized to the levels of a housekeeping gene, GAPDH.

Western blotting {#S18}
----------------

Cells from HEK293, HeLa, H9C2 and neonatal cardiac myocytes were lysed in extraction buffer (0.2% Triton X-100, 50mM NaCl, 5mM EDTA, 50mM Tris at pH 7.4 and complete EDTA-free protease inhibitor cocktail (Roche). Extracts were mixed with SDS sample buffer for degradation. The proteins were resolved by SDS-PAGE and transferred to nitrocellulose membrane and blotted for anti-β1AR (ab-3442- 1:1000), anti-SLC22A3 (ab124826-1:1000) or GAPDH (1:10,000) antibodies to detect β1AR, EMT/OCT3 and GAPDH expression by horseradish-peroxidase-conjugated rabbit IgG, sheep anti-mouse and rabbit IgG (1:10,000 Amersham Biosciences) and SuperSignal extended duration detection reagent (Pierce).

Internalization Assay by Flow Cytometry {#S19}
---------------------------------------

Internalization assay was carried out on HeLa cells transiently expressing Flag-tagged β~1~AR or β~2~AR. Cells were treated either with 10μM isoproterenol alone for 20min to promote endocytosis or pre-treated with 30μM Dyngo-4a for 15min to block endocytosis and then 10μM isoproterenol for 20 min at 37°C. Surface receptors were labelled by M1 anti-Flag antibody conjugated to Alexa 647 (Sigma, 1:1000) for 45min at 4°C. Cells were then collected in cold PBS and the fluorescence intensity profiles of cell populations (10,000 cells per sample) were measured using a FACS-Calibur instrument (BD Biosciences). In each experiment, triplicate samples were analysed for each condition. Experiments were carried out three times on three separate days.

Data availability {#S20}
-----------------

Our research resources, including methods, cells and protocols are available upon request. All reagents developed, such as FRB and FKBP constructs, as well as detailed methods will be available upon request. The corresponding author adheres to the NIH Grants Policy and Sharing of Unique Research Resources.
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![Golgi localized β~1~AR achieve an activated conformation upon extracellular ligand application\
**a**, Representative β~1~AR expressing HeLa cell showing Nb80-GFP (green) and Golgi Marker (GalT-mRFP) (red) localization at the indicated time after 10 μM epinephrine addition (*n* = 18 cells, Pearson's coefficient=0.67, 4 biological replicates, left); Representative individual Nb80--GFP line scans (arrowheads and arrow indicate plasma membrane and Golgi recruitment, respectively, right). **b**, Representative β~1~AR expressing HeLa cell showing Nb80--GFP (green) and Golgi Marker (GalT-mRFP) (red) localization at the indicated time after 10 μM dobutamine addition, cells were pre-treated with 10 μM ICI118551 (β~2~AR selective antagonist) 20 min before addition of dobutamine (*n* = 25 cells, Pearson's coefficient=0.71, 7 biological replicates). **c,** Confocal images showing permeabilized cells labelled with conjugated Alexa-555 flag tagged-β~1~AR (red) and Nb80-GFP (green) localization at the indicated time after 10 μM dobutamine addition, cells were pre-treated with 10 μM ICI118551 (**β**~2~AR selective antagonist) 20 min before addition of dobutamine (n=19 cells, 2 biological replicates, arrow indicate Golgi-localized β~1~AR). **d,** Comparison of β~2~AR and β~1~AR internalization after 20 min 10 μM epinephrine treatment in HeLa cells by flow cytometry with and without Dyngo-4a treatment (bars represents mean ± s.e.m., 3 biological replicates). **e,** Representative surface-labelled β~1~AR expressing HeLa cell pre-treated with 30 μM Dyngo-4a (dynamin inhibitor) and labelled with conjugated Alexa-647 flag tagged-β~1~AR (cyan), Nb80-mApple (red) and Golgi Marker (GalT-GFP) (green) at the indicated time after 10 μM epinephrine addition (*n* = 10 cells, Pearson's coefficient=0.5, 4 biological replicates, Yellow arrowheads indicates Golgi localization). Scale bars, 10 μm.](nihms858767f1){#F1}

![Golgi-localized β~1~AR activates Gs-mediated cAMP response\
**a**, Confocal image of HeLa cell showing Gs-turquoise (top panel) or endogenous Gs (bottom panel) in green and Golgi marker (GalT-mRFP) in red (representative of *n* = 12 and 35 cells, Pearson's coefficient=0.62 and 0.48 respectively, 2 biological replicates). Arrow and arrowheads indicate Gs plasma membrane and Golgi localization.**b**, Confocal images showings surface-labelled β~1~AR (cyan), Nb37--GFP (green) and GalT-mRFP (red) at indicated time points after agonist addition (representative of *n* = 12 cells, Pearson's coefficient=0.33, 3 biological replicates). Arrow and arrowhead indicate Nb37-GFP recruitment to the PM and Golgi, respectively. Insets show higher magnification. **c.** Top, confocal images of H9C2 cells treated with control or β~1~AR siRNA and labelled with anti-β~1~AR (green) and GalT-mRFP (red) (representative of *n* = 44 and 46 cells respectively, Pearson's coefficient=0.55 and0.26 from 5 and 3 biological replicates). Bottom-left, average Pearson's coefficient of anti-β~1~AR antibody (green) and GalT-mRFP (red) in control or β~1~AR knockdown cells (bars represents mean ± s.e.m., 3 biological replicates; p\<0.0001 by two-tailed unpaired t-test). Bottom-right, representative immunoblots from control and β~1~AR knockdown cells blotted for anti-β~1~AR antibody and GAPDH.Full images shown in [Supplementary Figure 3a](#SD2){ref-type="supplementary-material"}.Average knockdown was 82% of control (mean±SD, *n*=2). **d.** Confocal images of H9C2 cells expressing Nb80-GFP or Nb37-GFP before and after 10μM dobutamine treatment using anti-β~1~AR antibody (cyan) (representative of *n* = 24,16, 20 and 20 cells respectively, 3 biological replicates, arrows and arrowheads indicate plasma membrane and Golgi, respectively).Scale bar, 10 μm.](nihms858767f2){#F2}

![Rapamycin-inducible recruitment of Nb80 blocks β~1~AR-Gs coupling and inhibits Gs-mediated cAMP response at both the plasma membrane and the Golgi\
**a**, Representative images showing pVenus-FRB-Nb80 localization before and after rapamycin addition in HeLa cells expressing PM-FKPB (11-lyn-FKBP), top; or Golgi-FKBP (FKBP-GalT), bottom; (arrowhead and arrow shows plasma membrane and Golgi recruitment of pVenus-FRB-Nb80). **b**, Top, model for blocking β~1~AR-Gs coupling at the plasma membrane after recruitment of pVenus-FRB-Nb80. Bottom, forskolin-normalized β~1~AR-mediated cAMP response in the absence (dark blue bar) or presence (light blue bar) of 15 min pre-treatment of 1 μM rapamycin, rapamycin plus 100μM sotalol (red bar) (mean ± s.e.m., *n* = 4 biological replicates). Statistical significance was tested using two tailed unpaired *t* test (*p* =0.0008 and 0.3744 respectively). **c**, Top, model for blocking β~1~AR-Gs coupling at the Golgi membrane after recruitment of pVenus-FRB-Nb80. Bottom, forskolin-normalized β~1~AR-mediated cAMP response in the absence (dark blue bar) or presence (light blue bar) of 15 min pre-treatment of 1 μM rapamycin or rapamycin plus 100μM sotalol (red bar) (mean ± s.e.m., *n* = 7 biological replicates). Statistical significance was tested using two tailed unpaired *t* test (*p* \<0.0001 and 0.0001, respectively). **d.** Effect of 1μM rapamycin on forskolin-mediated cAMP response (*n*=10 biological replicates). Scale bars, 10 μm.](nihms858767f3){#F3}

![Epinephrine accesses the Golgi-localized β~1~AR pool via corticosterone-sensitive membrane transport\
**a**, Examples of membrane permeant and membrane impermeant β adrenergic agonists. **b**, Confocal image of HeLa cell expressing β~1~AR and Nb80-mApple, showing distinct localization of Nb80-mApple (red) and Dextran-647 (green) after pulse-chased labelling with Dextran-647 for 20 min and 10μM epinephrine treatment at the same time (*n* = 25 cells, Pearson's coefficient=0.18, 3 biological replicates).**c.** Lysates from indicated cells were probed with anti-SLC22A3 (anti-EMT/OCT3) and anti- GAPDH antibody to control for equal loading and expression. Full images shown in [Supplementary Figure 6](#SD2){ref-type="supplementary-material"}. **d**. Confocal image of HeLa cells stained with anti-SLC22A3 (anti-EMT/OCT3) showing plasma membrane (yellow arrow) and intracellular membrane (yellow arrowhead) localization (*n* = 26 cells, 3 biological replicates). **e.** Representative β~1~AR expressing HEK293 cell showing Nb80--GFP (green) and Golgi Marker (GalT-mRFP) (red) localization at the indicated time after 10 μM epinephrine (middle row, Pearson's coefficient=0.26) and dobutamine (bottom row, Pearson's coefficient=0.63) addition (*n* = 11 cells, 2 biological replicates). **f.** Representative β~1~AR expressing HeLa cell showing Nb80--GFP (green) and Golgi Marker (GalT-mRFP) (red) localization at the indicated time after 10 μM epinephrine (middle row, Pearson's coefficient=0.15) and dobutamine (bottom row, Pearson's coefficient=0.68) addition. Cells were pre-treated with 10μM corticoesterone for 15 min (*n* = 12 cells, 3 biological replicates). Scale bars, 10 μm.](nihms858767f4){#F4}

![Pharmacological manipulations differentially regulate β~1~AR compartmentalized signalling\
**a**, Examples of membrane permeant and membrane imperment β adrenergic antagonist and their effects on plasma membrane and Golgi signalling. **b**, Confocal image frames of activated β~1~AR expressing HeLa cells with 10 μM dobutamine showing Nb80-GFP (green) and Golgi marker colocalization followed by reversal with 10 μM Metoprolol (top) (*n*= 3 cells, 3 biological replicates) or 100μM Sotalol (middle) (*n*= 5 cells, 3 biological replicates) or 5mM Sotalol (bottom) addition at indicated time points (arrowheads indicate Golgi localization of Nb80-GFP after addition of 100μM and 5mM Sotalol for 20min). **c,** Time course and **d.** maximum forskolin-normalized β~1~-AR-mediated cAMP response by 10 μM dobutamine (dark blue), pre-treated with 10 μM Metoprolol (red), 100 μM sotalol (light blue), 5mM sotalol (grey) (mean ± s.e.m., *n*=3 biological replicates). Statistical significance was tested using two tailed unpaired *t* test (*p \<*0.0001, *p* =0.0035 and *p* =0.034 respectively). Scale bars, 10 μm.](nihms858767f5){#F5}

![Pharmacological manipulations differentially regulate β~1~AR-mediated PKA activation on the Golgi\
**a.** Confocal image frames of β~1~AR expressing HeLa cells treated with 10 μM dobutaine at indicated time points (*n*= 7 cells, 4 biological replicates). **b.** Confocal image frames of β~1~AR expressing HeLa cells pre-treated with 5mM sotalol and upon addition of 10μM dobutaine at indicated time points (*n*= 9 cells, 4 biological replicates). **c.** Confocal image frames of β~1~AR expressing HeLa cells pre-treated with 10μM metoprolol and upon addition of 10μM dobutamine at indicated time points (*n*= 5 cells, 4 biological replicates). **d.** Kinetics of PKA Cα-YFP translocation from the Golgi membrane in cells treated with 10μM dobutamine (blue), 10μM metoprolol+10μM dobutamine (red) or 5mM sotalol+ 10μM dobutamine; the fluorescent intensity of PKA Cα-YFP was normalized by PKA RIIβ-mCherry fluorescent (*n*= 7, 5 and 9, 4 biological replicates) (see methods).Scale bars, 10 μm.](nihms858767f6){#F6}
